80%Confidence
0Views
FDASource
2026-04-08Date
Summary
Macleods Pharma's Class II recall for subpotent Levothyroxine Sodium tablets suggests manufacturing inconsistencies that could affect patient outcomes and regulatory standing. This may lead to increased scrutiny from the FDA and potential market share loss to competitors.
Actionable: Evaluate the competitive landscape for thyroid medications, as this recall may create opportunities for other manufacturers.
AI Confidence: 80%
Data Points
firmMACLEODS PHARMA USA, INC
classificationClass II
statusOngoing
distributionNationwide
productLevothyroxine Sodium Tablets USP 150 mcg, 1000 Tablets bottle, Rx Only, Manufactured for: Macleods Pharma USA, Inc., Princeton, NJ, Manufactured by: M
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now